Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.
暂无分享,去创建一个
Mauro D'Amico | Dino Amadori | Oriana Nanni | Paolo Bruzzi | Matteo Puntoni | O. Nanni | D. Amadori | M. Stockler | M. Sormani | P. Bruzzi | N. Wilcken | Alessandra Gennari | A. Decensi | M. Puntoni | A. Gennari | Andrea DeCensi | Nicholas Wilcken | Martin Stockler | Mariapia Sormani | M. D’amico
[1] J. Mayordomo,et al. Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Ruíz,et al. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study , 2010, Breast Cancer Research and Treatment.
[3] Seema A Khan,et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions : Explanation and Elaboration , 2009 .
[5] B. Kavanagh,et al. Reply to X. Mirabel , 2009 .
[6] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[7] Kristine Broglio,et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Gelmon,et al. The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.
[9] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[10] O. Nanni,et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Orlandini,et al. Survival of metastatic breast carcinoma patients over a 20‐year period , 2005, Cancer.
[12] R. Rouzier,et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Stockler,et al. Duration of chemotherapy for metastatic breast cancer , 2004 .
[14] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[15] M. Stockler,et al. Chemotherapy for Advanced Breast Cancer – How Long Should it Continue? , 2003, Breast Cancer Research and Treatment.
[16] J. Klijn,et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. , 2003, European journal of cancer.
[17] E. Eisenhauer,et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Sledge,et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Powles,et al. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. , 1997, European journal of cancer.
[20] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[21] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[22] C. Spurr,et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.
[23] J. Carmichael,et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer , 1990, The Lancet.
[24] M. Tattersall,et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.
[25] K. Markou,et al. National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .
[26] H. Mouridsen,et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. , 1993, European journal of cancer.